Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 655130 induction therapy in biologic-experienced ulcerative colitis
NL-OMON48554Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of spesolimab in autoimmune colitis, sponsored by Boehringer Ingelheim. Started Mar 2018; status: active, not recruiting.
02
Drugs
spesolimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON48554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48554.